The company's flagship product, Barricaid, is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier - that is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The Barricaid has been studied in a definitive randomized superiority trial with over 550 patients enrolled, with treated patients found superior on both endpoints, with significantly lower rates of symptomatic recurrences, index-level reoperations, and device or procedure related serious adverse events.